Carrie Van Der Weyden Selected Research

KIR3DL2 Receptors

8/2018

IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carrie Van Der Weyden Research Topics

Disease

3	T-Cell Lymphoma (Lymphoma, T Cell) 05/2021 - 01/2019
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2019 - 08/2018
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2019
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2019
1	Mycosis Fungoides 08/2018
1	Coinfection 01/2017
1	Neoplasms (Cancer) 01/2017
1	Sezary Syndrome (Sezary Erythroderma) 01/2017
1	Primary Cutaneous Anaplastic Large Cell Lymphoma 01/2017

Drug/Important Bio-Agent (IBA)

1	10-propargyl-10-deazaaminopterin FDA Link 01/2021
1	Brentuximab VedotinIBA 01/2019
1	KIR3DL2 ReceptorsIBA 08/2018
1	Monoclonal AntibodiesIBA 08/2018
1	Alemtuzumab (Campath)FDA Link 01/2017

Therapy/Procedure

3	Therapeutics 05/2021 - 01/2017
1	Art Therapy 01/2017